好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Social Determinants of Health in Diagnosing Creutzfeldt-Jakob Disease
Neurohospitalist
P2 - Poster Session 2 (2:45 PM-3:45 PM)
093

Investigating the relationship between patient demographics and diagnostic workup in patients with Creutzfeldt-Jakob Disease (CJD).

Diagnosis of CJD is challenging and often requires multimodal evaluation. Impact of patient demographics in accurate diagnosis of CJD is crucial, yet currently understudied.

This was a single-center retrospective analysis conducted at Stanford University. 38 patients with ICD10 diagnosis of CJD were identified. Demographic information, including sex (F=27, M=11), ethnicity (35 white (4 Hispanic), 3 Asian), age (56-82), and insurance type were obtained to evaluate whether these factors led to significantly different neurodiagnostic workup (MRI, LP, RT-Quic, 14-3-3, EEG, autoimmune encephalitis (AE) panel). Difference of proportions hypothesis test was conducted.  Age of diagnosis, and time-to-diagnosis from first symptom onset were retrospectively reviewed and a two-tailed t-test was used to investigate whether these differed significantly among different demographic groups.


Average age of diagnosis was 67.0, and average time-to-diagnosis from symptom onset was 4.4 months. 97% of patients got MRI; 95% EEG; 92% LP; 71% RT-Quic; 71% 14-3-3; 63% AE panel. Male patients were diagnosed faster than female patients based on first symptom-onset (2.7 vs. 5.0 months), but got less RT-Quic (45% vs. 81%) and 14-3-3 (45% vs. 81%). Hispanic patients got less RT-Quic (25% vs. 76%) and 14-3-3 (50% vs. 74%) compared to non-Hispanic patients. Patients older than 65 took longer to diagnose (4.6 vs. 4.2 months). Lastly, patients with private insurance compared to public had more RT-Quic sent (86% vs. 63%), and were diagnosed at a younger age (61.7 vs. 70.0), but took longer to diagnose (5.8 vs. 3.5 months).

Our single-center study demonstrates that demographic features may play an important role in diagnostic pursuits in patients with CJD. Further multicenter studies, including patients of differing backgrounds to better reflect the larger service community, will elucidate the intricate relationships among each social determinants of health.

Authors/Disclosures
Nathanael J. Lee, MD, PhD (Nathanael Lee)
PRESENTER
Dr. Lee has nothing to disclose.
Jeffrey E. Dunn, MD, FAAN (Stanford University Medical Center) Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics. Dr. Dunn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna Therapeutics. Dr. Dunn has received intellectual property interests from a discovery or technology relating to health care.
Kristin M. Galetta, MD (Stanford University) Dr. Galetta has received personal compensation in the range of $0-$499 for serving as a Speaker with Can Do MS.